Genomics R&D firm, Ryogen LLC, has been awarded two U.S. Patents - its 33rd and 34th - that are directed to polynucleotide sequences that play critical roles in Diabetes and Hepatitis C.

Ryogen LLC was awarded two U.S. Patents for genes with biomedical research, diagnostic and drug development potential, bringing Ryogen's intellectual property portfolio to seven issued patents in addition to 15 patent applications.